Chapter 39: Antibiotics That Inhibit Bacterial Protein Synthesis

Antibiotics That Inhibit Bacterial Protein Synthesis presentation explores the pharmacological foundations of antibiotics that disrupt bacterial protein synthesis by targeting the specific structural differences between prokaryotic and eukaryotic ribosomes. While animal cells utilize 40S and 60S ribosomal subunits, bacteria rely on 30S and 50S components, allowing drugs to selectively inhibit bacterial translation without harming the host. Within the group targeting the 30S subunit, aminoglycosides such as gentamicin and amikacin exert bactericidal effects by causing genetic misreading, while tetracyclines like doxycycline provide bacteriostatic coverage by preventing transfer RNA from binding to the ribosome. These medications require clinical vigilance; for instance, aminoglycosides are associated with potential renal impairment and hearing loss, and tetracyclines can cause permanent tooth discoloration in children and photosensitivity in adults. The discussion further examines agents acting on the 50S subunit, including macrolides like azithromycin, which are frequently used for respiratory ailments, and clindamycin, which is essential for treating anaerobic infections despite its link to serious gastrointestinal complications. Additionally, the chapter reviews specialized treatments for multidrug-resistant pathogens, such as linezolid and quinupristin-dalfopristin for resistant enterococci and staphylococci, alongside topical options like mupirocin for skin infections. Comprehensive insights into drug metabolism, excretion routes, and the rising challenge of bacterial resistance mechanisms—such as efflux pumps and enzymatic inactivation—provide a vital framework for understanding modern antimicrobial therapy.